Novartis is penning a four-year pact with ProFound Therapeutics to create new therapeutics for heart disease, with $750 ...

Novartis and ProFound Therapeutics have entered into a four-year partnership aimed at discovering and developing new ...

Using the ProFoundry platform and Novartis' expertise, the partners will identify novel proteins and drug targets for cardiovascular disease.

Cambridge, USA-based ProFound Therapeutics today announced a four-year collaboration with Swiss pharma giant Novartis to ...

ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular Disease Provided by GlobeNewswire Jun 26, 2025, 10:30 ...

ProFound Therapeutics enters multi-year strategic collaboration with Novartis to discover and develop novel therapeutics for cardiovascular disease: Cambridge, Massachusetts Frida ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Novartis entered into a four-year partnership with Flagship Pioneering’s ProFound Therapeutics to discover and develop novel protein therapies for cardiovascular conditions.. The deal, announced ...

CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProFound™ Therapeutics, a company pioneering the expanded human proteome to develop first-in-class medicines for multiple diseases, today announced ...

Chip Wilson, the visionary entrepreneur who fundamentally reshaped the world of athletic apparel with Lululemon, is now ...